Safety profiling of CAR-T cells using an organotypic human tissue platform
Machado, A.; Birsen, G.; Rajnpreht, I.; Furtado Peter, I.; Colell, S.; Marzal, B.; Fredon, M.; Ziegler-Martin, K.; Martinez Bedoya, D.; Fumagalli, M.; Vimeux, L.; Davanture, S.; Melchiore, F.; Thomas, A.; Collet, M.; Fremand, X.; Burroni, B.; Laugel, B.; Lupo-Mansuet, A.; Prieto, M.; Damotte, D.; Le Doussal, J.-M.; Luu, M.; Dutoit, V.; Garnache-Ottou, F.; Guedan, S.; Migliorini, D.; Donnadieu, E.
Show abstract
CAR-T-cell-associated on-target off-tumor (OTOT) toxicity represents a major safety concern, as recognition of target antigens on healthy tissues can trigger severe and potentially life-threatening complications. Predicting OTOT toxicity remains a challenge because current preclinical models fail to capture the complexity of native human tissues. Here, we developed a human organotypic tissue platform that enables functional assessment of CAR-T-cell activity in intact human tissues across organ-specific and inflammatory contexts. Using a panel of clinically relevant CAR-T-cell products with known OTOT toxicities, we demonstrate that the platform faithfully recapitulates clinically observed tissue-specific toxicity profiles. CAR-T cells targeting EGFR, HER2, and mesothelin induced inflammatory and cytotoxic responses in healthy human lung tissue, whereas CD19 CAR-T cells remained inactive. We further show that OTOT toxicity cannot be reliably predicted from antigen abundance alone but instead results from the integration of multiple target-dependent determinants, including CAR affinity, inflammatory context, antigen accessibility, and effector-cell dose. The platform also enables quantitative assessment of inflammatory and cytotoxic responses and supports evaluation of pharmacological and CAR design-based strategies to mitigate toxicity. Together, this work establishes the first human organotypic platform for functional modeling of CAR-T-cell-associated OTOT toxicity, providing a clinically relevant framework for preclinical safety evaluation and the rational development of safer engineered cell therapies. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=167 SRC="FIGDIR/small/740527v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@2b47e2org.highwire.dtl.DTLVardef@17c7ce2org.highwire.dtl.DTLVardef@1eaf9feorg.highwire.dtl.DTLVardef@1c295bb_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 96%
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 95%
- Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting 95%
Similar papers in this journal
- Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastoma 96%
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies 95%
- Intratumor Childhood Vaccine-Specific CD4+ T cell Recall Coordinates Antitumor CD8+ T cells and Eosinophils 95%
Similar papers in this journal
- Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Immunity 96%
- A functional screening platform for engineering chimeric antigen receptors with reduced on-target, off-tumour activation 94%
- Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cell therapy 94%
Similar papers in this journal
- Collagen-binding IL-12 expressing STEAP1 CAR-T cells reduce toxicity and eradicate mouse prostate cancer in combination with checkpoint inhibitors 97%
- Immunometabolic cues recompose and reprogram the microenvironment around biomaterials 94%
- Efficient and multiplexed somatic genome editing with Cas12a mice 94%
Similar papers in this journal
- Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis 94%
- Versatile workflow for cell type resolved transcriptional and epigenetic profiles from cryopreserved human lung. 94%
- Enhancing CAR-T Cell Metabolism to Overcome Hypoxic Conditions in the Brain Tumor Microenvironment 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.